More articles from Targeting Drug Resistance: Poster Presentations - Proffered Abstracts

Abstract B50: Preclinical efficacy of combined MEK and Src inhibition: MEK inhibitor reverses resistance to Src inhibitor therapy in ovarian cancer cells
Fiona Simpkins, Diana Azzam, Joyce M. Slingerland

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B50; DOI: 10.1158/1078-0432.OVCA13-B50
Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer
Barbie Taylor-Harding, Hasmik Agadjanian, Paul Joseph Aspuria, Takako Mizuno, Dong-Joo Cheon, Sandra Orsulic, Beth Karlan, Christine Walsh, Wolf Ruprecht Wiedemeyer

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B48; DOI: 10.1158/1078-0432.OVCA13-B48
Abstract B52: The bromodomain inhibitor JQ1 enhances cisplatin-mediated cytotoxicity in ovarian cancer cells
Dineo Khabele, Andrew J. Wilson, Jeanette Saskowski, Scott W. Hiebert

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B52; DOI: 10.1158/1078-0432.OVCA13-B52
Abstract B51: Management of ascites via the alfa-pump closed system in platinum-resistant-ovarian-cancer (PROC): A model of sequential non-invasive tumor-cell sampling through the urinary bladder
Christina Fotopoulou, Laura Spiers, Delali Adjogatse, Emily Pickford, Roberto Dina, Sara Blagden, Nagy Habib, Hani Gabra

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B51; DOI: 10.1158/1078-0432.OVCA13-B51
Abstract B49: The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer
Jimmy Belotte, Nicole Fletcher, Awoniyi Awonuga, Mitchell Alexis, Husam Abu-soud, Michael Diamond, Mohammed Saed, Ghassan Saed

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B49; DOI: 10.1158/1078-0432.OVCA13-B49
Abstract A36: Protein markers of tumor-initiating cells and mitochondrial function in ovarian cancer
Marike Gabrielson, My Björklund, Joseph Carlson, Maria Shoshan

Clinical Cancer Research Oct 2013, 19 (19 Supplement) A36; DOI: 10.1158/1078-0432.OVCA13-A36
Abstract A54: Evaluation of effect of metformin and its various combinations on epithelial ovarian cancer
Seema Patel, Neeta Singh

Clinical Cancer Research Oct 2013, 19 (19 Supplement) A54; DOI: 10.1158/1078-0432.OVCA13-A54
Abstract A48: Anti-tumor activity of the MEK inhibitor pimasertib in combination with the PI3K/mTOR inhibitor SAR245409 in low-grade serous ovarian cancer
Sukhvinder S. Sidhu, Frank Campana, Coumaran Egile, Karl Hsu, Samantha Goodstal, Ekaterine Asatiani, Lars Damstrup, Joanne Lager, Janet Ogden, Loic Vincent

Clinical Cancer Research Oct 2013, 19 (19 Supplement) A48; DOI: 10.1158/1078-0432.OVCA13-A48
Abstract B35: Target discovery: Using VBIM technique to identify carboplatin resistance genes in ovarian cancer cells
Han Wei, Tao Lu

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B35; DOI: 10.1158/1078-0432.OVCA13-B35
Abstract B47: microRNA-181a plays a critical role in ovarian cancer progression through the regulation of epithelial-mesenchymal transition
Aditya Parikh, Christine Lee, Peronne Joseph, Sergio Marchini, Alessia Baccarini, Valentin Kolev, Chiara Romualdi, Robert Fruscio, Hardik Shah, Wang Feng, Gavriel Mullokandov, David Fishman, Maurizio D'Incalci, Jamal Rahaman, Tamara Kalir, Raymond Redline, Brian D. Brown, Goutham Narla, Analisa DiFeo

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B47; DOI: 10.1158/1078-0432.OVCA13-B47

Main menu

User menu

Search

More articles from Targeting Drug Resistance: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About Clinical Cancer Research